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ABSTRACT
Objectives: Chronic myelogenous leukemia (CML) is a progressive,
largely fatal cancer. Emerging treatments may prolong life; however, these
result in additional monetary costs. Accurate estimation of their economic
impact requires reliable estimates on preferences for health states. The
purpose was to estimate preference weights from the general population in
four developed countries for standardized health states experienced by
persons with CML.
Methods: Time trade-off preferences with a 10-year time horizon were
elicited for CML-related health states using an interviewer-administered
survey from convenience samples in Canada (n = 103), the United States
(n = 74), the UK (n = 97), and Australia (n = 79). Standardized descrip-
tions of seven CML-related health states (characterizing chronic, acceler-
ated and blast phases, each with responding and nonresponding state, and
adverse events of treatment) were derived in consultation with oncologists.
Generalized linear models were used to estimate whether utilities, adjusted
for age and sex, differed by country.
Results: The mean age of the sample (n = 357) was 45 years and 46%
were male. Mean unadjusted preference values of CML-related health
states ranged from 0.84 for “Chronic phase responding to treatment” to
0.21 for “Blast phase, not responding to treatment.” For each phase,
preferences were lower for the nonresponding state. After adjustment for
age and sex, considerable variability was observed in mean preference
values between countries.
Conclusion: These data quantify the deteriorating impact of CML disease
progression and the impact of nonresponse to treatment. The study results
add to evidence from other disease areas that systematic differences exist
in preference values between countries.
Keywords: chronic myelogenous leukemia, health state utility, preferences,
societal, utility assessment.
Introduction
Leukemia has an annual incidence of more than 300,000 cases
globally, approximately 15% of which are the chronic myelog-
enous type, and is almost uniformly fatal if untreated [1].
Although up to one-third of patients with chronic lymphocytic
leukemia will never require therapy [2], the median survival
time for patients with untreated chronic myelogenous leukemia
(CML) is 4 to 5 years [3], and only a few months for patients
with acute leukemias [4]. Before the introduction of tyrosine
kinase inhibitors for CML [5–12], treatment for leukemia
largely consisted of bone marrow transplantation or interferon
and/or chemotherapy. Although effective at prolonging survival,
the latter therapies are associated with severe toxic side effects
[13–20] with attendant negative impacts on quality-of-life
[21–23]. With tyrosine kinase inhibitor treatment, which is
associated with fewer toxicities and prolongs survival compared
to interferon [5–12,24–26] chronic-phase CML patients may
persist at pretreatment quality-of-life levels for long periods
[22].
Therapies for leukemia including CML are expensive [27,28]
and the economic burden is substantial [29]. Quantifying the
patient-perceived impact of therapies therefore becomes a critical
outcome, particularly to compare the cost-effectiveness of treat-
ment options. Although knowing that one is receiving or
responding to treatment can have a substantial positive psycho-
logical effect on patients with cancer [30], this may be counter-
acted by the negative impact of toxicities [21–23] and
uncertainty about the future [31,32]. Health status utility esti-
mation enables one to quantify preferences for selected health
outcomes and ultimately, to quality-adjust life expectancy.
To date, preferences for leukemia health states have only
been measured for CML. Existing CML utilities are based only
on EQ-5D quality-of-life scores elicited from chronic phase
patients in the International Randomized Interferon (IFN)
versus ST1571 (IRIS) Study [22,33–35]. For utilities for accel-
erated or blast phase patients health states, we rely on hypo-
thetical EQ-5D utilities generated by clinician or community
member samples [27,28]. Use of the EQ-5D is subject to the
following limitations: it is not as sensitive to disease-speciﬁc
impacts as direct methods like the time trade-off (TTO)
approach [36]; as it focuses on current health status, it cannot
explicitly measure key psychological effects such as knowing
that one is responding to treatment; and it cannot control for
the idiosyncratic variation which can be substantial in cancer
[37]. The IRIS-based chronic phase utilities represented pooled
data from respondents from all participating countries; nationa-
lity, however, has been previously shown to be an important
predictor of health state utility in other disease areas [38,39].
In no study were standardized, disease-speciﬁc health states
valuated.
The objective of this study was to estimate TTO preference
values for standardized CML health states that consider disease
stage and responsiveness to treatment, among respondents from
the general population in Canada, the United States, the UK, and
Australia.
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Methods
Health State Development
Health states for evaluation were developed through literature
review, clinical expert consultation, and feedback from trained
quality-of-life researchers.
Draft health state descriptions were based on the EQ-5D
generic quality-of-life instrument [40], literature describing
symptoms at each stage of CML, and the World Health Organi-
zation cancer classiﬁcation scheme [11–14,41–48]. Each CML
health state described the typical patient experience according to
a set of key domains, enabling balanced descriptions across the
health states. These domains included: symptoms, pain, and dis-
comfort; emotional status; effects on activities of daily living; and
future outlook. Each disease phase was also considered accord-
ing to whether patients were responding to treatment. One health
state for treatment cessation due to serious adverse events (SAEs)
was also constructed. In all, seven CML-related health states
were developed.
Health states were reﬁned after iterative review by four clini-
cal experts. An interview discussion guide was used by trained
interviewers to query clinical experts on the nature of CML
disease phases in terms of our identiﬁed key domains. Experts
also considered each phase according to whether patients were
responding, or not responding, to treatment. Information from
the clinical expert interviews was used to reﬁne the draft health
states, which were reexamined in a second round of clinical
expert interviews for content and context validity.
Agreement was reached among the experts on the content of
the ﬁnal health states, which were as follows:
Chronic phase responding to treatment;
Chronic phase not responding to treatment;
Accelerated phase responding to treatment;
Accelerated phase not responding to treatment;
Blast phase responding to treatment;
Blast phase not responding to treatment; and
Treatment withdrawal due to SAEs.
Full health state descriptions are listed in Table 1.
The health states were designed to be easily comprehensible
from the general public’s perspective, and gender-neutral.
Pilot Testing
The health states were pilot tested in TTO interviews [49], with
four members of the general public, one from the United States,
UK, Canada, and Australia. After interview completion, partici-
pants were debriefed to identify any problems with health state
content, or comprehensibility and language issues. No issues
emerged from the pilot testing, and no revisions were made.
TTO Respondents
Members of the general public provided preference values for
the seven CML-related health states. Respondents had to be at
least 18 years of age (19 in Canada), without CML. Potential
respondents were excluded if they were not English-speaking, if
they had known cognitive impairment, or if in the interviewer’s
opinion they were incapable of understanding the exercise. A
convenience sample of respondents were recruited through
newspaper advertising, in an approximately 50:50 ratio of
males to females. Recruitment occurred between July 2006 and
November 2007. All respondents received remuneration for
participation.
Sample Size
This study was designed to collect data from a minimum of 300
individuals; this was not determined by a formal power analysis
partly because there was no speciﬁc hypothesis being tested. The
target sample size was established within the context of insufﬁ-
cient knowledge about the psychometric properties of TTO utili-
ties, characterized by: lack of information on variability, little
guidance on the range of minimally clinically important differ-
ences, and inadequate understanding of the impact of demo-
graphic and cultural factors on utilities. The sample size thus
represented a compromise between precision, cost, speed of data
collection, and the need to maximize the number of responses.
Useful but arbitrary heurisitics have been suggested for utility
measurement: 0.1 being the minimal clinically important differ-
ence (or conﬁdence interval [CI] around the mean estimate) [50],
and standard deviations being greater for the general public (0.3)
than for patient (0.2) groups [50,51]. Based on those rules of
thumb, we aimed to recruit at least 300 participants, with a
minimum of 75 per site. That sample size yielded a predicted CI
of 0.07 below the target of 0.1 and CI estimates around country-
speciﬁc mean utilities of +0.073. This sample size is consistent
with other published studies [37,52].
Data Collection
Data were collected through one-on-one interviews. To standard-
ize the preference elicitation exercise, all interviewers received
study-speciﬁc training. Interviews were conducted using an inter-
view script, and a TTO board prop with a 10-year time horizon
[49].
Each TTO elicitation interview consisted of the respondent
reading a short, nontechnical description of CML, a review of the
health states without names, and a description of the TTO
process and prop. Respondents were then asked to rank the
health states from most to least favorable to ensure comprehen-
sion of the task, and the health states were presented in random
order for valuation.
Preference values for each of the seven CML-related health
states were estimated using the TTO technique. For each health
state, respondents were required to choose between: 1) remaining
in the health state without improvement for 10 years; or 2)
trading a number of remaining years of life for receipt of a
hypothetical treatment that would restore the person to full
health. The process incorporated a “ping-pong” approach,
wherein probabilities are traded back and forth between higher
and lower values that iteratively narrowed to the point of in-
difference [50].
Sociodemographic information was also collected. All
respondents provided written informed consent before beginning
the TTO exercise. This study complied with the tenets of the
Declaration of Helsinki.
Data Analysis
The data from the four countries were compiled and checked for
errors. Data entry was validated by double entry before data
analysis. Demographic data were summarized by means or pro-
portions, and compared between countries using analysis of vari-
ance or the chi-square test, as appropriate.
A decision rule was applied to the data to exclude responses
from participants who may have misunderstood the exercise.
Health state valuations from respondents who valued chronic
phase responding to treatment, as being equal to or worse than
blast phase not responding to treatment, were excluded from
analysis. Nevertheless, as a sensitivity analysis, we also analyzed
the data with the illogical responses included.
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Individual TTO preference values were calculated for each
health state for each respondent by dividing the number of years
that the respondent would live in perfect health by the 10-year
time horizon. Mean TTO preference values and the correspond-
ing 95% CI were calculated for each health state, and compared
according to country, age category, and sex.
We did not recruit according to age-speciﬁc strata. To stan-
dardize the preference values according to age and sex, two types
of models were considered: Gaussian with an identity link (i.e.,
ordinary least squares) and a gamma family with a log link [53].
The second model was considered because the ordinary least
squares model has the disadvantage of potentially predicting
values above the upper boundary (i.e., 1.0). Given that prefer-
ence values may be non-normal and bounded by 1.0, we modeled
(1–utility). The goodness of ﬁt was compared using the model
deviances. We also explored the effect of demographic variables
Table 1 Standardized health state descriptions for seven CML-related states
Chronic phase responding to treatment
• I have recently been diagnosed with a serious health condition and have started receiving treatment. My doctor told me that my treatment is working.
This has relieved my anxiety but I worry about having a serious health condition.
• I am able to continue with my work and daily activities.
• I need blood tests at the hospital approximately every 3 months and bone marrow is taken for examination every 6 months. This test is painful and I am in
discomfort for a few days afterwards.
Chronic phase not responding to treatment
• I have recently been diagnosed with a serious health condition and have started receiving treatment. My doctor told me that my treatment is not working.
This has made me anxious and upset.
• I am currently able to continue with my work and daily activities.
• I need blood tests at the hospital approximately once a month and bone marrow is taken for examination every 3 months. This test is painful and I am in
discomfort for a few days afterwards.
• I worry about my condition getting worse and I worry about my family. I understand that my health condition may get worse. I avoid making plans for the
future.
Accelerated phase responding to treatment
• I have been diagnosed with a serious health condition and am receiving treatment. My blood tests show that my condition is getting worse and my doctor has
told me that my treatment is working. This has relieved some of my anxiety but I still worry about having a serious health condition.
• I am currently able to continue with my work and daily activities.
• I am visiting the hospital for blood tests once or twice a month and bone marrow is taken for examination every 3 months. This test is painful and I am in
discomfort for a few days afterwards.
• I know that my current level of health may change in the months to come and that my health condition may get worse. I worry about my family, which makes
me feel frustrated and depressed. I avoid making plans for the future.
Accelerated phase not responding to treatment
• I have been diagnosed with a serious health condition and am receiving treatment. My blood tests show that my condition is getting worse and my doctor
told me that my treatment is not working. I am now taking more medication than before, am more anxious and worry a lot about having a serious health
condition.
• I am no longer able to continue work or complete daily activities although I am able to wash and dress myself.
• I sometimes have a fever and sweat and I have lost some weight.
• I am visiting the hospital for transfusions approximately every 3 months and for blood tests twice a month. Bone marrow is taken for examination every
3 months. This test is painful and I am in discomfort for a few days afterwards.
• I am scared about dying and concerned about the impact this will have on my family.
Blast phase responding to treatment
• I have been diagnosed with a serious health condition am receiving treatment. My blood tests show that my condition is getting much worse and I have been
very ill. My doctor told me that my treatment is working. This has relieved some of my anxiety but I still worry about having a serious health condition.
• I am unable to return to work and undertake the daily activities as I am frequently at the hospital for tests and am still not feeling very well.
• I sometimes have a fever and sweat and I have lost more weight.
• I feel tired and weak and sometimes short of breath, but the transfusions help this.
• I am visiting the hospital for transfusions every month and blood tests twice a month. Bone marrow is taken for examination every 3 months. This test is
painful and I am in discomfort for a few days afterwards.
• I understand that my symptoms will probably get worse again soon and I avoid making plans for the future. I am scared about dying and concerned about the
impact this will have on my family but I am less depressed than I was when I was very ill.
Blast phase not responding to treatment
• I have been diagnosed with a serious health condition and am receiving treatment. My blood tests show that my condition is getting much worse and I have
been very ill. My doctor told me my treatment is not working.
• I am now unable to care for myself and am conﬁned to my bed and will be staying at the hospital until I die.
• I sometimes have a fever and sweat and I have lost more weight.
• I am tired and weak, often short of breath and can easily catch infections, but the transfusions help a little.
• I receive transfusions every 2 weeks and blood tests every week. Bone marrow is taken for examination once a month.This test is painful and I am in
discomfort for a few days afterwards.
• I am scared about dying and concerned about the impact this will have on my family. I feel anxious and depressed.
Treatment withdrawal due to serious adverse events
• I have been diagnosed with a serious health condition and have stopped receiving treatment.
• My doctor withdrew my treatment because I experienced one or several of the following symptoms:
• Muscle cramps and a skin rash which stopped me from sleeping
• Bleeding in my intestines
• Large decrease in my white cell and platelet count
• Fluid or blood build up in my chest
• Severe vomiting
• Severe diarrhea
• Suicidal thoughts
• I am relieved that I no longer have to take the treatment.
• I am anxious that my leukemia will get worse without medication.
• I am scared about dying and concerned about the impact this will have on my family.
CML, chronic myelogenous leukemia.
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that differed signiﬁcantly between countries on mean health state
utility, by univariate and multivariable gamma models.
The ﬁnal generalized linear model was ﬁt using a gamma
distribution with a log link. Age was entered into the model as a
continuous variable, and sex was coded as 1 for male. The model
was used to determine the effect of age (in years) and sex among
both groups of respondents and whether preferences differed by
country. All statistical comparisons were two-tailed and used an
alpha of 0.05.
Results
The study sample comprised 357 participants, interviewed at the
four study sites (Table 2). Based on the decision rule excluding
inconsistent answers, 18 (5%) responses were omitted: 3 from
Australia (ﬁnal n = 79), 0 from the UK (n = 97), 14 from Canada
(n = 89), and 1 from the United States (n = 74). The mean age
was 44.9 years, with age distributions varying across countries
(P = 0.007). Recruitment into the youngest age category (<30)
ranged from 16.5% (Australia) to 25.6% (United States). Thirty-
ﬁve percent of Australian respondents were in the oldest (>60)
age category, compared with 9.5% of respondents in the US
sample. Approximately equal proportions of males (43% (UK)–
49% (United States); mean = 46%) were recruited between the
countries (P = 0.813). Some signiﬁcant differences in the distri-
bution of marital and education status were also seen between
the countries (P < 0.001).
The ordering of health states by TTO utilities showed vari-
ability between countries (Table 3). All seven CML-related health
states were associated with decreases in preference values from
full health. Chronic phase responding to treatment was consis-
tently ranked as the most preferred health state, with a mean
utility of 0.84 in the overall sample (from 0.78 in Canada/the
United States, to 0.91 in the UK). The second- and third-most
preferred health states in all countries were accelerated phase
responding to treatment, and chronic phase not responding to
treatment (mean utilities in the overall sample, 0.70 and 0.66,
respectively). Blast phase not responding to treatment was con-
sistently the least preferred health state, with a mean utility of
0.21 in the overall sample (ranging from 0.12 in Australia to 0.29
in the UK). Mean utilities for accelerated phase not responding to
treatment, blast phase responding to treatment, and treatment
withdrawal due to SAEs were not consistently ordered between
the countries, although the mean utilities for these states by
country were similar. Mean utilities for each phase were lower in
the nonresponding, compared with the responding, state.
Table 2 Sociodemographic characteristics of layperson respondents, from whom utilities for CML-related health states were elicited*
Characteristic
Number (%); or mean (SD; range)
Total
(n = 339)
Australia
(n = 79)
United Kingdom
(n = 97)
Canada
(n = 89)
United States
(n = 74) P-value
Male sex 157 (46.3) 37 (46.8) 41 (42.3) 43 (48.3) 36 (48.6) 0.813
Age, year 44.9 (15.9;18–79) 49.3 (18.5;19–79) 43.2 (14.0;18–78) 46.0 (16.3;19–75) 41.1 (13.3;22–78) 0.007
Country
Canada 89 (26.3)
United Kingdom 97 (28.6)
Australia 79 (23.3)
United States 74 (21.8)
Race 0.023
Oceanian* 65 (27.0) 65 (82.3) 0 (0) 0 (0) 0 (0)
White 114 (47.3) 13 (16.5) 0 (0) 50 (56.2) 51 (68.9)
Asian 24 (10.0) 1 (1.3) 0 (0) 22 (24.7) 1 (1.4)
Mixed 12 (5.0) 0 (0) 0 (0) 5 (5.6) 7 (9.5)
Other 26 (10.8) 0 (0) 0 (0) 11 (12.4) 15 (20.3)
Unknown† 0 (0) 97 (100) 1 (1.1) 0 (0)
Marital status‡ <0.001
Single 99 (40.9) 21 (26.6) 0 (0) 41 (46.1) 37 (50)
Married/Common-law 101 (41.7) 44 (55.7) 0 (0) 26 (29.2) 31 (41.9)
Separated/Divorced 30 (12.4) 6 (7.6) 0 (0) 18 (20.2) 6 (8.1)
Widowed 12 (5.0) 8 (10.1) 0 (0) 4 (4.5) 0 (0)
Unknown 0 (0) 97 (100) 0 (0) 0 (0)
Employment category‡ 0.176
Full-time employed 158 (46.6) 34 (43) 45 (46.4) 37 (41.6) 42 (56.8)
Part-time employed 65 (19.2) 10 (12.7) 26 (26.8) 19 (21.3) 10 (13.5)
Retired 50 (14.7) 20 (25.3) 12 (12.4) 13 (14.6) 5 (6.8)
At home 13 (3.8) 2 (2.5) 7 (7.2) 3 (3.4) 1 (1.4)
Student 22 (6.5) 6 (7.6) 4 (4.1) 3 (3.4) 9 (12.2)
Seeking work 15 (4.4) 2 (2.5) 2 (2.1) 6 (6.7) 5 (6.8)
Unemployed 10 (2.9) 3 (3.8) 1 (1) 4 (4.5) 2 (2.7)
Unknown 6 (1.8) 2 (2.5) 0 (0) 4 (4.5) 0 (0)
Education category‡ <0.001
None 3 (0.9) 0 (0) 3 (3.1) 0 (0) 0 (0)
GCSE levels 19 (5.6) 1 (1.3) 17 (17.5) 1 (1.1) 0 (0)
High school 87 (25.7) 34 (43) 13 (13.4) 25 (28.1) 15 (20.3)
College diploma/degree 65 (19.2) 15 (19) 19 (19.6) 25 (28.1) 6 (8.1)
Undergraduate degree 105 (31) 23 (29.1) 29 (29.9) 21 (23.6) 32 (43.2)
Postgraduate degree 56 (16.5) 6 (7.6) 16 (16.5) 13 (14.6) 21 (28.4)
Unknown 4 (1.2) 0 (0) 0 (0) 4 (4.5) 0 (0)
*Oceanian refers to Australians, Australian Aboriginals, Australian South Sea, and Torres Strait Islanders [67]; however, the vast majority of Oceanian Australian respondents were white
Australians of European origin.
†Sample sizes for “unknown” are exclusive of UK participants, as these data were not collected from the UK.
‡As some respondents did not answer all questions, the number of valid responses for each characteristic differs.
CML, chronic myelogenous leukemia; GCSE, general certiﬁcate of secondary education.
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Considerable variability was observed in mean preference
values for health states between countries. The difference in mean
preferences between countries for individual health states ranged
from a minimum of 0.13 (between the UK [0.91] and Canada/
United States [0.78] for chronic phase responding to treatment)
to 0.18 (between the UK [0.53] and the United States [0.35] for
accelerated phase not responding to treatment). Respondents
from the UK generated the highest unadjusted mean preference
values; Canadian and US participants responded similarly on
average, and tended to report the lowest unadjusted mean pre-
ferences. Reanalysis of the results with illogical responses
included demonstrated little variation in overall responses; the
point estimates of mean utility and standard deviation varied
little (<0.02) with the inclusion of the illogical responses,
although the CI tended to widen slightly. Slightly increased varia-
tion in the point estimates for the more preferred health states
was seen in the Canadian sample. Mean preference values with
95% CI, for the entire study sample and by country, with the
inclusion and exclusion of illogical responses, are presented in
Table 4.
Mean preference values for the seven health states were cal-
culated by country, according to age category and sex (Table 5).
Table 3 Distributions of layperson TTO utilities for seven CML-related health states, according to country of residence of respondent
Respondents
Health state
CR CNR AR ANR BR BNR SAEs
All
(n = 339)
Mean 0.84 0.66 0.70 0.44 0.46 0.21 0.46
95%CI 0.82, 0.86 0.63, 0.68 0.67, 0.72 0.41, 0.47 0.43, 0.48 0.19, 0.23 0.42, 0.49
Median 0.90 0.70 0.80 0.50 0.50 0.10 0.45
IQR 0.7, 1 0.5, 0.8 0.5, 0.9 0.2, 0.6 0.25, 0.6 0.05, 0.3 0.2, 0.7
Australian
(n = 79)
Mean 0.85 0.68 0.71 0.40 0.44 0.12 0.52
95%CI 0.81, 0.89 0.63, 0.72 0.67, 0.76 0.34, 0.45 0.38, 0.49 0.09, 0.15 0.45, 0.59
Median 0.90 0.70 0.80 0.40 0.50 0.10 0.50
IQR 0.8, 0.96 0.6, 0.8 0.53, 0.9 0.2, 0.58 0.2, 0.6 0.03, 0.18 0.28, 0.8
United Kingdom
(n = 97)
Mean 0.91 0.73 0.78 0.53 0.56 0.29 0.52
95%CI 0.89, 0.94 0.69, 0.78 0.74, 0.82 0.48, 0.58 0.52, 0.6 0.24, 0.33 0.46, 0.58
Median 1.00 0.80 0.80 0.50 0.60 0.20 0.50
IQR 0.9, 1 0.6, 0.9 0.7, 0.9 0.4, 0.7 0.5, 0.7 0.1, 0.5 0.3, 0.8
Canada
(n = 89)
Mean 0.78 0.61 0.62 0.46 0.39 0.25 0.35
95%CI 0.74, 0.83 0.55, 0.66 0.57, 0.67 0.41, 0.51 0.34, 0.45 0.21, 0.29 0.29, 0.41
Median 0.90 0.65 0.60 0.50 0.40 0.20 0.30
IQR 0.65, 1 0.4, 0.8 0.5, 0.8 0.2, 0.6 0.2, 0.5 0.1, 0.4 0.1, 0.5
United States
(n = 74)
Mean 0.78 0.60 0.66 0.35 0.42 0.15 0.44
95%CI 0.74, 0.83 0.53, 0.66 0.59, 0.72 0.28, 0.41 0.35, 0.48 0.11, 0.19 0.36, 0.51
Median 0.90 0.70 0.70 0.30 0.40 0.05 0.45
IQR 0.7, 0.9 0.43, 0.8 0.5, 0.9 0.06, 0.5 0.05, 0.68 0.05, 0.1 0.1, 0.7
CML, chronic myelogenous leukemia; TTO, time trade-off; CI, conﬁdence interval; IQR, interquartile range; CR, chronic phase responding to treatment; CNR, chronic phase not responding to
treatment;AR, accelerated phase responding to treatment;ANR, accelerated phase not responding to treatment; BR, blast phase responding to treatment; BNR, blast phase not responding to
treatment; SAEs, treatment withdrawal due to serious adverse events.
Table 4 Distributions of layperson TTO utilities for seven CML-related health states, according to country of residence of respondent, with illogical
responses excluded or included
Respondents
Logical
responses
Health state
CR CNR AR ANR BR BNR SAEs
All Excluded Mean 0.84 0.66 0.70 0.44 0.46 0.21 0.46
(n = 339) 95%CI 0.82, 0.86 0.63, 0.68 0.67, 0.72 0.41, 0.47 0.43, 0.48 0.19, 0.23 0.42, 0.49
Included Mean 0.82 0.64 0.68 0.44 0.45 0.22 0.45
(n = 357) 95%CI 0.79, 0.84 0.61, 0.69 0.65, 0.71 0.41, 0.47 0.42, 0.48 0.19, 0.24 0.42, 0.48
Australian Excluded Mean 0.85 0.68 0.71 0.40 0.44 0.12 0.52
(n = 79) 95%CI 0.81, 0.89 0.63, 0.72 0.67, 0.76 0.34, 0.45 0.38, 0.49 0.09, 0.15 0.45, 0.59
Included Mean 0.85 0.67 0.70 0.40 0.44 0.12 0.52
(n = 82) 95%CI 0.81, 0.90 0.62, 0.72 0.67, 0.75 0.34, 0.45 0.38, 0.49 0.09, 0.15 0.45, 0.59
United Kingdom Excluded Mean 0.91 0.73 0.78 0.53 0.56 0.29 0.52
(n = 97) 95%CI 0.89, 0.94 0.69, 0.78 0.74, 0.82 0.48, 0.58 0.52, 0.6 0.24, 0.33 0.46, 0.58
Included Mean 0.91 0.73 0.78 0.53 0.56 0.29 0.52
(n = 97) 95%CI 0.89, 0.94 0.69, 0.78 0.74, 0.82 0.48, 0.58 0.52, 0.6 0.24, 0.33 0.46, 0.58
Canada Excluded Mean 0.78 0.61 0.62 0.46 0.39 0.25 0.35
(n = 89) 95%CI 0.74, 0.83 0.55, 0.66 0.57, 0.67 0.41, 0.51 0.34, 0.45 0.21, 0.29 0.29, 0.41
Included Mean 0.73 0.56 0.58 0.44 0.38 0.26 0.34
(n = 103) 95%CI 0.67, 0.78 0.51, 0.62 0.52, 0.63 0.40, 0.49 0.34, 0.43 0.22, 0.30 0.28, 0.39
United States Excluded Mean 0.78 0.60 0.66 0.35 0.42 0.15 0.44
(n = 74) 95%CI 0.74, 0.83 0.53, 0.66 0.59, 0.72 0.28, 0.41 0.35, 0.48 0.11, 0.19 0.36, 0.51
Included Mean 0.78 0.60 0.66 0.35 0.42 0.16 0.44
(n = 75) 95%CI 0.74, 0.83 0.53, 0.67 0.59, 0.72 0.29, 0.42 0.35, 0.49 0.11, 0.20 0.37, 0.52
CML, chronic myelogenous leukemia; TTO, time trade-off; CI, conﬁdence interval; IQR, interquartile range; CR, chronic phase responding to treatment; CNR, chronic phase not responding
to treatment; AR, accelerated phase responding to treatment;ANR, accelerated phase not responding to treatment; BR, blast phase responding to treatment; BNR, blast phase not responding
to treatment; SAEs, treatment withdrawal due to serious adverse events.
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The effect of sex and age category on mean health state prefer-
ence values was inconsistent across health states and countries.
Generally, younger respondents demonstrated the widest range in
mean preference values across all health states; they rated the
most preferred health states the highest and the least preferred
health states the lowest. Mean preference values were typically
lowest in the oldest age category. For most health states in most
countries, mean preference values were similar between males
and females. The largest differences in mean health state prefer-
ence values between the sexes, consistent between countries,
were associated with the SAEs health state.
Although estimates of model ﬁt were similar between the
Gaussian and the gamma models, the Gaussian model predicted
values that were not between 0 and 1. The gamma model was
therefore used to adjust mean preference values. There were
signiﬁcant differences between countries for all mean health state
preference values except for the stopped treatment due to adverse
events health state; age and sex were signiﬁcant predictors of
some, but not all, mean health state preference values. Education
and marital status were inconsistently associated with mean
health state utilities for some countries; due to the inconsisten-
cies, no adjustment was made for these factors. Table 6 presents
country-speciﬁc preference values adjusted for age and sex, with
model deviances for the overall model. Adjustment for age and
sex did not change the rank ordering of the health states for the
combined data, or by country. Chronic phase responding to
treatment was consistently ranked as the most preferred health
state, with an adjusted mean preference value of 0.91 in the
overall sample (ranging from 0.85 in the UK, to 0.94 in Austra-
lia). The second- and third-most preferred health states in all
countries were accelerated phase responding to treatment, and
chronic phase not responding to treatment (mean preferences in
the overall sample, 0.78 and 0.73, respectively). Blast phase not
responding to treatment was consistently the least preferred
health state, with a mean preference value of 0.22 overall
(ranging from 0.02 in Australia to 0.31 in the UK). The greatest
range in adjusted mean preference values was seen among Aus-
tralians; UK respondents demonstrated the least variability
between adjusted preference value estimates for the health states.
Discussion
We found that the development and progression of CML is
associated with substantial decreases in preferences for CML-
related health states, from the general public’s perspective. Pre-
ferences for health states deteriorate dramatically as CML health
Table 5 Mean TTO utilities for 339 layperson respondents for seven CML-related health states, according to age category and sex
n CR CNR AR ANR BR BNR SAEs
Australian respondents (n = 79)
Age (year)
<30 13 0.89 0.72 0.70 0.26 0.30 0.06 0.65
30–39 15 0.93 0.75 0.79 0.50 0.49 0.08 0.68
40–49 11 0.88 0.65 0.77 0.36 0.39 0.13 0.50
50–59 12 0.85 0.69 0.74 0.46 0.46 0.17 0.56
60 28 0.78 0.63 0.65 0.39 0.48 0.14 0.36
Sex
Male 37 0.87 0.71 0.72 0.39 0.45 0.14 0.58
Female 42 0.83 0.65 0.71 0.40 0.43 0.10 0.47
United Kingdom respondents (n = 97)
Age (year)
<30 13 0.88 0.60 0.77 0.45 0.45 0.24 0.33
30–39 34 0.93 0.79 0.81 0.57 0.59 0.34 0.56
40–49 22 0.91 0.78 0.82 0.56 0.57 0.26 0.63
50–59 14 0.95 0.69 0.80 0.51 0.56 0.29 0.52
60 14 0.89 0.67 0.67 0.48 0.58 0.26 0.43
Sex
Male 41 0.94 0.77 0.81 0.59 0.57 0.29 0.55
Female 56 0.90 0.70 0.77 0.49 0.55 0.28 0.50
Canadian respondents (n = 89)
Age (year)
<30 18 0.86 0.63 0.68 0.56 0.42 0.25 0.42
30–39 16 0.78 0.64 0.62 0.40 0.36 0.29 0.28
40–49 16 0.87 0.73 0.68 0.56 0.52 0.26 0.42
50–59 17 0.78 0.60 0.65 0.43 0.31 0.18 0.33
60 22 0.67 0.47 0.51 0.37 0.37 0.26 0.30
Sex
Male 43 0.79 0.62 0.62 0.46 0.33 0.24 0.31
Female 46 0.78 0.59 0.62 0.46 0.45 0.25 0.38
US respondents (n = 74)
Age (year)
<30 19 0.84 0.68 0.69 0.46 0.49 0.19 0.51
30–39 17 0.77 0.56 0.65 0.30 0.44 0.11 0.39
40–49 18 0.78 0.66 0.71 0.34 0.44 0.14 0.47
50–59 13 0.73 0.45 0.63 0.27 0.37 0.20 0.36
60 7 0.74 0.56 0.51 0.30 0.20 0.06 0.41
Sex
Male 36 0.76 0.56 0.63 0.31 0.42 0.14 0.36
Female 38 0.81 0.63 0.69 0.38 0.41 0.16 0.51
CML, chronic myelogenous leukemia;TTO, time trade-off; CR, chronic phase responding to treatment; CNR, chronic phase not responding to treatment;AR, accelerated phase responding to
treatment;ANR, accelerated phase not responding to treatment; BR, blast phase responding to treatment; BNR, blast phase not responding to treatment; SAEs, treatment withdrawal due to
serious adverse events.
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states grow progressively more critical. Poorer health states in
CML, such as blast phase not responding to treatment, were
associated with extremely low adjusted preference values
(average, 0.22). Even the preference value for the most preferred
state (chronic phase responding to treatment, average 0.91) rep-
resents a substantial reduction compared to full health. The
impact of increasingly severe CML health states on treatment
preferences, through the direct elicitation of preference values,
had never previously been measured.
Existing preference values for CML are based on chronic
phase patient responses to the EQ-5D survey, measured as part of
the IRIS Study [22,33–35]. A drawback to the use of generic
utility measures like the EQ-5D is that the representativeness of
the data are limited by the inclusion criteria of the trial within
which the measure is administered. Should utilities for speciﬁc
disease phases be required, these data will be limited if the
number of patients experiencing the events is low [37]. The
commonly used preference value for chronic phase CML is
0.854, from newly diagnosed chronic phase patients in IRIS [22].
This utility value does not consider treatment response status,
and greatly overestimates the mean utility we measured for the
chronic phase not responding to treatment health state (0.71). As
IRIS patients were all in the chronic phase, there is little infor-
mation on utilities for accelerated- or blast-phase patients. Utili-
ties of from 0.58 to 0.595 for the accelerated phase and 0.38 for
the blast phase of CML have been employed in modeling exer-
cises, but were based on clinical expert completion of the EQ-5D
only [34,35]. Physician-based utilities have been shown to inac-
curately reﬂect the utilities of both the general public and patients
in varied disease areas [54–57], including cancer [58–62].
General public preference weightings remain the preferred option
for organizations such as the National Institute for Health and
Clinical Excellence (NICE) and the Washington Panel on Cost
Effectiveness [63,64]; many reimbursement agencies including
the Common Drug Review do not accept expert-derived utility
values.
The validity and applicability of IRIS utility estimates may be
further limited as they are based on a pooling of data from many
countries. In the present study, we demonstrate that country can
be an important determinant of preference value. Signiﬁcant
differences were observed in mean health state preference values
by country, for all health states except blast phase not responding
to treatment and treatment withdrawal due to SAEs. Only a few
previous utilities studies have examined country-speciﬁc differ-
ences in utility estimates [38,39]. Our study extends upon these
ﬁndings by being the ﬁrst to measure differences between coun-
tries for leukemia health state preference values among general
public respondents. We are presently undertaking a study to
validate the current ﬁndings by eliciting responses from CML
patients in the same four countries. Comparing the results elic-
ited from the general public and patients in the same country will
provide greater insight into the generalizability of the ﬁndings,
the differences in responses between the different types of respon-
dents, and potential predictors such as response to treatment and
disease phase.
Signiﬁcant differences were also noted for most health state
preference values according to respondent age (except in the UK);
mean adjusted preference values declined with increasing age.
Sex, however, was not signiﬁcantly associated with mean health
state preference values, when considered in association with age
and country. Nevertheless, we chose to adjust for age and sex to
present standardized, comparable preference values between the
countries. The statistical adjustment had a relatively large effect
size, likely due to the differences in the underlying age distribu-
tions of the study samples.
Strengths of our study included the use of standardized health
state descriptions developed through literature review and clini-
cal expert opinion, which were pilot tested to ensure face validity
and the validity of the resultant CML health state preference
values. We attempted to make our sample representative of the
target population by recruiting according to the sex distribution
of each country from which we recruited respondents. Although
we did not recruit according to age, we adjusted our ﬁnal mean
preference value estimates to compensate for differences in the
age distributions of the target populations.
This study was subject to a number of limitations. First,
although feedback from patients with CML would have vali-
dated the content of the health states, for practical reasons we did
not include patient interviewing in the health state development
process. Instead, we relied on feedback from four clinical experts
who treat CML to validate the content of the health states.
Second, participant recruitment was only undertaken in one city
in each country, and respondents may not have been broadly
representative of the target population as a whole. Although
NICE and the Washington Panel recommend the use of general
public-based utilities, individual treatment decisions may be
better based on patient-provided preference values [50,65]. Vali-
dating our health states and general public-based utilities in a
patient population may be advantageous to satisfy both regula-
tory and individual decision makers. Third, as we believed that
the health-related quality of life impact of treatment-related tox-
icities would be limited due to the short duration of these con-
sidered in the context of an already poor prognosis, we did not
measure utilities for these separately. Rather, we developed one
health state to capture all patients who had to stop treatment due
to severe toxicity, which we did feel would be important from
Table 6 Age- and sex-adjusted TTO utilities (95% CI) for 339 layperson respondents for seven CML-related health states, according to country
Country CR CNR AR ANR BR BNR SAEs
Overall 0.91 0.73 0.78 0.49 0.48 0.22 0.58
(0.87, 0.93) (0.66, 0.79) (0.71, 0.83) (0.41, 0.56) (0.39, 0.56) (0.15, 0.29) (0.50, 0.65)
Deviance 206.1 151.0 165.6 87.4 86.1 37.2 141.8
Australia 0.94 0.78 0.79 0.37 0.30 0.02 0.75
(0.88, 0.97) (0.66, 0.85) (0.65, 0.87) (0.18, 0.52) (0.10, 0.48) (0, 0.05) (0.60, 0.84)
United Kingdom 0.85 0.68 0.79 0.50 0.50 0.31 0.48
(0.61, 0.94) (0.48, 0.81) (0.62, 0.88) (0.33, 0.63) (0.31, 0.63) (0.14, 0.44) (0.25, 0.64)
Canada 0.91 0.72 0.73 0.59 0.49 0.28 0.48
(0.82, 0.95) (0.58, 0.81) (0.60, 0.82) (0.45, 0.69) (0.33, 0.61) (0.15, 0.40) (0.30, 0.61)
United States 0.89 0.75 0.79 0.52 0.59 0.22 0.58
(0.78, 0.94) (0.57, 0.85) (0.62, 0.88) (0.34, 0.65) (0.40, 0.72) (0.07, 0.34) (0.38, 0.76)
CML, chronic myelogenous leukemia; TTO, time trade-off; CI, conﬁdence interval; CR, chronic phase responding to treatment; CNR, chronic phase not responding to treatment; AR, accelerated
phase responding to treatment; ANR, accelerated phase not responding to treatment; BR, blast phase responding to treatment; BNR, blast phase not responding to treatment; SAEs, treatment
withdrawal due to serious adverse events.
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the patient’s perspective. The assumption that the incremental
disutility of additional treatment-related toxicities would be
minimal could beneﬁt from a separate, empirical evaluation.
Fourth, as required by the TTO exercise, we assumed that the
relationship between the duration of living in a health state and
an individual’s utility value for that health state was independent.
This assumption has been challenged in a study using EQ-5D
health states that found that preferences decline with increasing
durations of severe health states [66]; further empirical investi-
gation may reveal whether these effects hold true for the TTO
exercise or health state valuations in cancer, and whether our
elicited utility values overestimate true preferences for CML
health states. Lastly, although the inclusion of illogical responses
in the data set had little effect on the point estimates of mean
utility in general, some variation was seen in the point estimates
for mean utility for the more preferred health states among
Canadian respondents. Modelers making use of these data may
include responses from the full data set in sensitivity analyses to
further explore the effect of this variability on cost-effectiveness
ratios.
Our study is the ﬁrst to provide a direct measure of prefer-
ences for standardized CML-related health states, which incor-
porate information on both the clinical course and treatment
responsiveness in CML, from the general public’s perspective.
The preference values estimated in our study demonstrate that
whether an individual is responding to treatment is an important
determinant, as is disease phase and country of residence.
Summary utility values for only chronic phase patients, or
patients with accelerated/blast phase disease, provide inaccurate
estimates by both under- and overestimating the impact of CML.
The preference values obtained through this study will provide a
means for direct comparison between health states, and for
quality-adjusting life years, in economic evaluations of treat-
ments for CML.
Source of ﬁnancial support: This study was presented in part at the Annual
Meeting of the International Society for Pharmacoeconomics & Outcomes
Research (ISPOR) European Congress 2007. Funding for this study was
provided by Bristol-Myers Squibb Company.
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